A Single-dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Octreotide Injection in Healthy Adult Subjects
Latest Information Update: 12 Oct 2023
Price :
$35 *
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly; Solid tumours
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 07 Oct 2023 Status changed from recruiting to completed.
- 15 Mar 2023 New trial record
- 13 Mar 2023 Status changed from not yet recruiting to recruiting.